

# Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region

Christine F. Skibola,<sup>1,2,84,\*</sup> Sonja I. Berndt,<sup>3,84</sup> Joseph Vijai,<sup>4,84</sup> Lucia Conde,<sup>1,2,84</sup> Zhaoming Wang,<sup>5,84</sup> Meredith Yeager,<sup>5,84</sup> Paul I.W. de Bakker,<sup>6,7</sup> Brenda M. Birmann,<sup>8</sup> Claire M. Vajdic,<sup>9</sup> Jia-Nee Foo,<sup>10</sup> Paige M. Bracci,<sup>11</sup> Roel C.H. Vermeulen,<sup>7,12</sup> Susan L. Slager,<sup>13</sup> Silvia de Sanjose,<sup>14,15</sup> Sophia S. Wang,<sup>16</sup> Martha S. Linet,<sup>3</sup> Gilles Salles,<sup>17,18,19</sup> Qing Lan,<sup>3</sup> Gianluca Severi,<sup>20,21,22</sup> Henrik Hjalgrim,<sup>23</sup> Tracy Lightfoot,<sup>24</sup> Mads Melbye,<sup>23,25</sup> Jian Gu,<sup>26</sup> Hervé Ghesquière,<sup>19,27</sup> Brian K. Link,<sup>28</sup> Lindsay M. Morton,<sup>3</sup> Elizabeth A. Holly,<sup>11</sup> Alex Smith,<sup>24</sup> Lesley F. Tinker,<sup>29</sup> Lauren R. Teras,<sup>30</sup> Anne Krickler,<sup>31</sup> Nikolaus Becker,<sup>32</sup> Mark P. Purdue,<sup>3</sup> John J. Spinelli,<sup>33,34</sup> Yawei Zhang,<sup>35</sup> Graham G. Giles,<sup>21,22</sup> Paolo Vineis,<sup>20,36</sup> Alain Monnereau,<sup>37,38,39</sup> Kimberly A. Bertrand,<sup>8,40</sup> Demetrius Albanes,<sup>3</sup> Anne Zeleniuch-Jacquotte,<sup>41,42</sup> Attilio Gabbas,<sup>43</sup> Charles C. Chung,<sup>3</sup> Laurie Burdett,<sup>5</sup> Amy Hutchinson,<sup>5</sup> Charles Lawrence,<sup>44</sup> Rebecca Montalvan,<sup>44</sup> Liming Liang,<sup>40,45</sup> Jinyan Huang,<sup>40</sup> Baoshan Ma,<sup>40,46</sup> Jianjun Liu,<sup>10</sup> Hans-Olov Adami,<sup>40,47</sup> Bengt Glimelius,<sup>48,49</sup> Yuanqing Ye,<sup>26</sup> Grzegorz S. Nowakowski,<sup>13</sup> Ahmet Dogan,<sup>50</sup> Carrie A. Thompson,<sup>51</sup> Thomas M. Habermann,<sup>51</sup> Anne J. Novak,<sup>51</sup> Mark Liebow,<sup>51</sup> Thomas E. Witzig,<sup>51</sup> George J. Weiner,<sup>28</sup> Maryjean Schenk,<sup>52</sup> Patricia Hartge,<sup>3</sup> Anneclaire J. De Roos,<sup>29,53</sup> Wendy Cozen,<sup>54,55</sup> Degui Zhi,<sup>56</sup> Nicholas K. Akers,<sup>2</sup> Jacques Riby,<sup>1,2</sup> Martyn T. Smith,<sup>2</sup> Mortimer Lacher,<sup>4</sup> Danylo J. Villano,<sup>4</sup> Ann Maria,<sup>4</sup> Eve Roman,<sup>24</sup> Eleanor Kane,<sup>24</sup> Rebecca D. Jackson,<sup>57</sup> Kari E. North,<sup>58,59</sup> W. Ryan Diver,<sup>30</sup> Jenny Turner,<sup>60,61</sup> Bruce K. Armstrong,<sup>31</sup> Yolanda Benavente,<sup>14,15</sup> Paolo Boffetta,<sup>62</sup> Paul Brennan,<sup>63</sup> Lenka Foretova,<sup>64</sup> Marc Maynadie,<sup>65</sup> Anthony Staines,<sup>66</sup> James McKay,<sup>67</sup> Angela R. Brooks-Wilson,<sup>68,69</sup> Tongzhang Zheng,<sup>35</sup> Theodore R. Holford,<sup>70</sup> Saioa Chamosa,<sup>71</sup> Rudolph Kaaks,<sup>32</sup> Rachel S. Kelly,<sup>36,40</sup> Bodil Ohlsson,<sup>72</sup> Ruth C. Travis,<sup>73</sup> Elisabete Weiderpass,<sup>47,74,75,76</sup> Jacqueline Clavel,<sup>37,38</sup> Edward Giovannucci,<sup>8,40,77</sup> Peter Kraft,<sup>40,45</sup> Jarmo Virtamo,<sup>78</sup> Patrizio Mazza,<sup>79</sup> Pierluigi Cocco,<sup>43</sup> Maria Grazia Ennas,<sup>80</sup> Brian C.H. Chiu,<sup>81</sup> Joseph F. Fraumeni, Jr.,<sup>3</sup> Alexandra Nieters,<sup>82,85</sup> Kenneth Offit,<sup>4,85</sup> Xifeng Wu,<sup>26,85</sup> James R. Cerhan,<sup>13,85</sup> Karin E. Smedby,<sup>83,85</sup> Stephen J. Chanock,<sup>3,85</sup> and Nathaniel Rothman<sup>3,85</sup>

<sup>1</sup>Department of Epidemiology, School of Public Health and Comprehensive Cancer Center, Birmingham, AL 35233, USA; <sup>2</sup>Division of Environmental Health Sciences, University of California Berkeley School of Public Health, Berkeley, CA 94720, USA; <sup>3</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA; <sup>4</sup>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; <sup>5</sup>Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD 20877, USA; <sup>6</sup>Department of Medical Genetics and of Epidemiology, University Medical Center Utrecht, Utrecht 3584 CG, the Netherlands; <sup>7</sup>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht 3584 CX, the Netherlands; <sup>8</sup>Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; <sup>9</sup>Prince of Wales Clinical School, University of New South Wales, Sydney, NSW 2052, Australia; <sup>10</sup>Human Genetics, Genome Institute of Singapore, Singapore 138672, Singapore; <sup>11</sup>Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA 94118, USA; <sup>12</sup>Institute for Risk Assessment Sciences, Utrecht University, Utrecht 3508 TD, the Netherlands; <sup>13</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; <sup>14</sup>Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Català d'Oncologia, IDIBELL, Barcelona 8907, Spain; <sup>15</sup>Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona 8036, Spain; <sup>16</sup>Department of Cancer Etiology, City of Hope Beckman Research Institute, Duarte, CA 91030, USA; <sup>17</sup>Department of Hematology, Hospices Civils de Lyon, Pierre benite Cedex 69495, France; <sup>18</sup>Department of Hematology, Université Lyon-1, Pierre benite Cedex 69495, France; <sup>19</sup>Laboratoire de Biologie Moléculaire de la Cellule UMR 5239, Centre National de la Recherche Scientifique, Pierre benite Cedex 69495, France; <sup>20</sup>Human Genetics Foundation, Turin 10126, Italy; <sup>21</sup>Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC 3053, Australia; <sup>22</sup>Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, VIC 3010, Australia; <sup>23</sup>Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen 2300, Denmark; <sup>24</sup>Department of Health Sciences, University of York, York YO10 5DD, UK; <sup>25</sup>Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; <sup>26</sup>Department of Epidemiology, M.D. Anderson Cancer Center, Houston, TX 77030, USA; <sup>27</sup>Department of Hematology, Centre Léon Bérard, Lyon 69008, France; <sup>28</sup>Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA; <sup>29</sup>Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98117, USA; <sup>30</sup>Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA; <sup>31</sup>Sydney School of Public Health, The University of Sydney, Sydney, NSW 2006, Australia; <sup>32</sup>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg 69120, Germany; <sup>33</sup>Cancer Control Research, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada; <sup>34</sup>School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; <sup>35</sup>Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT 06520, USA; <sup>36</sup>MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK; <sup>37</sup>Environmental Epidemiology of Cancer Group, Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Villejuif Cedex 94807, France; <sup>38</sup>UMRS 1018, Université Paris Sud, Villejuif Cedex 94807, France; <sup>39</sup>Registre des hémapathies malignes de la Gironde, Institut Bergonié, Bordeaux Cedex 33076, France; <sup>40</sup>Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA; <sup>41</sup>Department of Population Health, New York University School of Medicine, New York, NY 10016, USA; <sup>42</sup>Cancer Institute, New York University School of Medicine, New York, NY 10016, USA; <sup>43</sup>Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Monserrato, Cagliari 09042, Italy; <sup>44</sup>Health Studies Sector, Westat, Rockville, MD 20850, USA; <sup>45</sup>Department of Biostatistics, Harvard School of Public

Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573,  $p = 5.79 \times 10^{-20}$ ) near *CXCR5*; 11q24.3 (rs4937362,  $p = 6.76 \times 10^{-11}$ ) near *ETSI*; 3q28 (rs6444305,  $p = 1.10 \times 10^{-10}$ ) in *LPP*; 18q21.33 (rs17749561,  $p = 8.28 \times 10^{-10}$ ) near *BCL2*; and 8q24.21 (rs13254990,  $p = 1.06 \times 10^{-8}$ ) near *PVT1*. In an analysis of the HLA region, we identified four linked HLA-DR $\beta$ 1 multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk ( $p_{\text{omnibus}} = 4.20 \times 10^{-67}$  to  $2.67 \times 10^{-70}$ ). Additional independent signals included rs17203612 in HLA class II (odds ratio [OR]<sub>per-allele</sub> = 1.44;  $p = 4.59 \times 10^{-16}$ ) and rs13130437 in HLA class I (OR<sub>per-allele</sub> = 1.23;  $p = 8.23 \times 10^{-9}$ ). Our findings further expand the number of loci associated with FL and provide evidence that multiple common variants outside the HLA region make a significant contribution to FL risk.

Follicular lymphoma (FL [MIM 613024]) is a common B cell malignancy characterized by a variable indolent clinical course that can take decades to manifest and, in some cases, can be followed by transformation to aggressive diffuse large B cell lymphoma (DLBCL).<sup>1,2</sup> The previous genome-wide association studies (GWASs) of relatively small sample sizes have revealed FL susceptibility loci in the human leukocyte antigen (HLA) class I and class II regions on 6p21.32-33.<sup>3-7</sup> To identify new FL susceptibility loci, we genotyped 2,301 FL case subjects and 2,854 control subjects of European descent from 22 studies (NCI FL GWAS) as part of a larger initiative using the Illumina OmniExpress Beadchip (Table S1; Figure S1 available online). All studies obtained informed consent from participants and approval from the respective Institutional Review Boards for this study. Cases were ascertained from cancer registries, clinics, or hospitals or through self-report verified by medical and pathology reports (Table S1). The phenotype information for all cases was reviewed centrally at the International Lymphoma Epidemiology Consortium (InterLymph) Data Coordinating Center, and cases were classified according to the proposed scheme by the InterLymph Pathology Working Group based on

the World Health Organization (WHO) classification (2008) (Table S1). Genotypes were called using Illumina GenomeStudio software, and quality-control duplicates showed >99% concordance. All initial data analyses and management were conducted using the Genotyping Library and Utilities (GLU), and extensive quality-control metrics were applied to the data. Specifically, monomorphic SNPs and SNPs with call rates <93% were removed, and samples with call rates  $\leq$ 93%, mean heterozygosity <0.25 or >0.33 based on the autosomal SNPs, or gender discordance (>5% heterozygosity on the X chromosome for males and <20% heterozygosity on the X chromosome for females) were excluded. Unexpected duplicates (>99.9% concordance) and first-degree relatives on the basis of identity-by-descent sharing with  $\text{Pi-hat} > 0.40$  were removed. Ancestry was assessed using the GLU struct.admix module, and participants with <80% European ancestry were also excluded (Figure S2). After these quality-control steps, 94% of the participants and 611,844 SNPs remained for analysis (Tables S2 and S3). Genotype data previously generated on the Illumina Omni2.5 BeadChip<sup>8</sup> from an additional 3,536 control subjects from 3 of the 22 studies (ATBC, CPSII, and PLCO) were

Health, Boston, MA 02115, USA; <sup>46</sup>College of Information Science and Technology, Dalian Maritime University, Dalian, Liaoning Province 116026, China; <sup>47</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden; <sup>48</sup>Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm 17176, Sweden; <sup>49</sup>Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala 75105, Sweden; <sup>50</sup>Departments of Laboratory Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; <sup>51</sup>Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA; <sup>52</sup>Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI 48201, USA; <sup>53</sup>Department of Environmental and Occupational Health, Drexel University School of Public Health, Philadelphia, PA 19104, USA; <sup>54</sup>Department of Preventive Medicine, USC Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; <sup>55</sup>Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; <sup>56</sup>Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35233, USA; <sup>57</sup>Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, OH 43210, USA; <sup>58</sup>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; <sup>59</sup>Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; <sup>60</sup>Department of Anatomical Pathology, Australian School of Advanced Medicine, Macquarie University, Sydney, NSW 2109, Australia; <sup>61</sup>Department of Histopathology, Douglass Hanly Moir Pathology, Macquarie Park, NSW 2113, Australia; <sup>62</sup>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; <sup>63</sup>Group of Genetic Epidemiology, Section of Genetics, International Agency for Research on Cancer, Lyon 69372, France; <sup>64</sup>Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno 656 53, Czech Republic; <sup>65</sup>EA 4184, Registre des Hémopathies Malignes de Côte d'Or, University of Burgundy and Dijon University Hospital, Dijon 21070, France; <sup>66</sup>School of Nursing and Human Sciences, Dublin City University, Dublin 9, Ireland; <sup>67</sup>Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer, Lyon 69372, France; <sup>68</sup>Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada; <sup>69</sup>Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada; <sup>70</sup>Department of Biostatistics, Yale School of Public Health, New Haven, CT 06520, USA; <sup>71</sup>Health Department, BioDonostia Research Institute, Basque Region 20014, Spain; <sup>72</sup>Department of Clinical Sciences, Division of Internal Medicine, Skåne University Hospital, Lund University, Malmö 205 02, Sweden; <sup>73</sup>Cancer Epidemiology Unit, University of Oxford, Oxford OX3 7LE, UK; <sup>74</sup>Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Breivika 9037, Norway; <sup>75</sup>Cancer Registry of Norway, Oslo 0304, Norway; <sup>76</sup>Department of Genetic Epidemiology, Folkhalsan Research Center, Helsinki 00250, Finland; <sup>77</sup>Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA; <sup>78</sup>Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki 00271, Finland; <sup>79</sup>Department of Hematology, Ospedale Nord, Taranto 74100, Italy; <sup>80</sup>Department of Biomedical Science, University of Cagliari, Monserrato, Cagliari 09042, Italy; <sup>81</sup>Department of Health Studies, University of Chicago, Chicago, IL 60637, USA; <sup>82</sup>Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg 79108, Germany; <sup>83</sup>Department of Medicine Solna, Karolinska Institutet, Stockholm 17176, Sweden

<sup>84</sup>These authors contributed equally to this work

<sup>85</sup>These authors contributed equally to this work in a supervisory role


\*Correspondence: cskibola@uab.edu

<http://dx.doi.org/10.1016/j.ajhg.2014.09.004>. ©2014 by The American Society of Human Genetics. All rights reserved.

**Table 1. Association Results for Loci and SNPs Associated with Risk of Follicular Lymphoma**

Chr	Nearest Gene(s)	SNP	Position <sup>a</sup>	Risk Allele <sup>b</sup>	Other Allele	RAF <sup>c</sup>	Stage	OR (95% CI)	p	Phet <sup>d</sup>	I <sup>2</sup> <sup>e</sup>	
<b>Known Locus</b>												
6p21.32	HLA region	rs12195582 (rs115374828)	32444544	T	C	0.465	NCI	1.88 (1.74–2.02)	$3.26 \times 10^{-58}$	–	–	
							0.498	previous GWAS	1.55 (1.33–1.80)	$1.10 \times 10^{-8}$		
							0.435	replication	1.75 (1.60–1.90)	$1.17 \times 10^{-37}$		
							–	combined	1.78 (1.69–1.88)	$5.36 \times 10^{-100}$	$2.75 \times 10^{-1}$	19.56
<b>Genome-wide Significant Loci</b>												
11q23.3	CXCR5	rs4938573	118741842	C	T	0.204	NCI	1.30 (1.19–1.43)	$5.97 \times 10^{-9}$	–	–	
							0.193	previous GWAS	1.37 (1.14–1.64)	0.0008		
							0.188	replication	1.39 (1.25–1.54)	$3.17 \times 10^{-10}$		
							–	combined	1.34 (1.26–1.43)	$5.79 \times 10^{-20}$	$7.69 \times 10^{-1}$	0.00
11q24.3	ETS1	rs4937362	128492739	T	C	0.456	NCI	1.16 (1.08–1.25)	$7.01 \times 10^{-5}$	–	–	
							0.465	previous GWAS	1.33 (1.16–1.54)	$5.90 \times 10^{-5}$		
							0.467	replication	1.17 (1.08–1.28)	0.0002		
							–	combined	1.19 (1.13–1.25)	$6.76 \times 10^{-11}$	$7.52 \times 10^{-1}$	0.00
3q28	LPP	rs6444305	188299902	G	A	0.276	NCI	1.16 (1.08–1.27)	0.0002	–	–	
							0.269	previous GWAS	1.30 (1.06–1.59)	0.01		
							0.281	replication	1.25 (1.14–1.37)	$2.21 \times 10^{-6}$		
							–	combined	1.21 (1.14–1.28)	$1.10 \times 10^{-10}$	$4.42 \times 10^{-1}$	0.00
18q21.33	BCL2	rs17749561	60783211	G	A	0.910	NCI	1.43 (1.25–1.61)	$2.18 \times 10^{-7}$	–	–	
							0.908	previous GWAS	1.23 (0.96–1.57)	$1.10 \times 10^{-1}$		
							0.905	replication	1.28 (1.10–1.49)	0.002		
							–	combined	1.34 (1.22–1.47)	$8.28 \times 10^{-10}$	$5.43 \times 10^{-2}$	49.37
8q24.21	PVT1	rs13254990	129076451	T	C	0.315	NCI	1.20 (1.11–1.30)	$8.39 \times 10^{-6}$	–	–	
							0.307	previous GWAS	1.15 (0.98–1.34)	0.08		
							0.315	replication	1.16 (1.06–1.27)	0.001		
							–	combined	1.18 (1.11–1.24)	$1.06 \times 10^{-8}$	$6.99 \times 10^{-1}$	0.00
<b>Suggestive Loci</b>												
17q25.3	C17orf62	rs3751913	80405552	C	T	0.121	NCI	1.25 (1.11–1.39)	0.0001	–	–	
							0.126	previous GWAS	1.42 (1.16–1.75)	0.0008		
							0.121	replication	1.14 (1.01–1.29)	0.04		
							–	combined	1.23 (1.14–1.33)	$2.24 \times 10^{-7}$	$2.59 \times 10^{-1}$	21.50
3q13.33	CD86	rs2681416	121817613	A	G	0.311	NCI	1.24 (1.15–1.35)	$6.73 \times 10^{-8}$	–	–	
							0.305	previous GWAS	1.15 (0.99–1.34)	0.06		
							0.329	replication	1.06 (0.97–1.15)	0.23		
							–	combined	1.16 (1.09–1.22)	$2.33 \times 10^{-7}$	$5.54 \times 10^{-4}$	72.83
18q12.3	SLC14A2	rs11082438	42865210	G	T	0.936	NCI	1.39 (1.18–1.61)	$4.65 \times 10^{-5}$	–	–	
							0.941	previous GWAS	1.46 (1.07–1.99)	0.02		
							0.935	replication	1.22 (1.02–1.46)	0.03		
							–	combined	1.33 (1.19–1.48)	$4.01 \times 10^{-7}$	$9.26 \times 10^{-1}$	0.00

<sup>a</sup>Position according to human reference NCBI37/hg19.<sup>b</sup>Allele associated with an increased risk of FL.<sup>c</sup>Risk allele frequency in controls.<sup>d</sup>Cochran's Q test heterogeneity p value.<sup>e</sup>I<sup>2</sup> heterogeneity index.



**Figure 1. Regional Plots of the FL-Associated Locus rs4938573 in 11q23.3**

Figure shows the association results from the NCI FL GWAS and stages 1 and 2 combined (red diamond), recombination hotspots, and LD plots.

(Table S2), and association testing was conducted separately for each study using SNPTTEST v.2 adjusted for age, sex, and significant principal components.

Association results from the NCI FL GWAS and the two previously genotyped GWASs (totaling 2,728 case subjects, 7,758 control subjects in stage 1) were analyzed in a meta-analysis using a fixed-effects inverse-variance method based on the  $\beta$  estimates and standard errors from each study. Only SNPs with information scores  $>0.3$  were included in the meta-analysis. In the stage 1 meta-analysis, we identified three non-HLA loci (11q23.3, 11q24.3, and 3q13.33) that reached genome-wide significance ( $p < 5 \times 10^{-8}$ ). To confirm these loci and discover additional loci, 11 non-HLA SNPs with  $p < 5 \times 10^{-6}$  from the stage 1 meta-analysis


also included, resulting in a total of 2,142 FL case subjects and 6,221 control subjects for analysis (NCI FL GWAS; Table S4).

To evaluate population substructure, a principal components analysis was conducted using the GLU struct.pca module. Plots of the top principal components are shown in Figure S3. Association testing was conducted assuming a log-additive genetic model adjusted for age, sex, and significant principal components. A quantile-quantile plot of the association results revealed an enrichment of SNPs with small  $p$  values even after removal of all SNPs in the HLA region, which has been previously reported to be associated with FL ( $\lambda = 1.018$ , Figure S4). In addition to the HLA region, one locus on 11q23.3 reached genome-wide statistical significance ( $p < 5 \times 10^{-8}$ ) (Figure S5).

To increase power to detect associations in stage 1, we added data on 586 FL case subjects and 1,537 control subjects from two independent previously published GWASs (UCSF2<sup>4</sup> and SCALE<sup>3</sup>) to the newly genotyped NCI FL GWAS (Tables S1 and S4; Figure S1). Because different genotyping platforms were used (Table S2), we imputed all three GWASs (NCI, UCSF2, SCALE) using the 1000 Genomes Project (1kGP) v.3 (March 2012 release) reference panel<sup>9</sup> and IMPUTE2.<sup>10</sup> The genotype data underwent rigorous quality control filters before imputation

were chosen for replication in stage 2. Only SNPs with a MAF  $> 1\%$  were considered for replication, and no SNPs were taken forward for replication in regions where they appeared to be singletons or obvious artifacts. Stage 2 replication was undertaken in a new set of 1,795 FL case subjects and 5,586 control subjects, which included 119 case subjects and 349 control subjects from another GWAS (UCSF1/NHS) genotyped on the OmniExpress microarray and imputed using IMPUTE2<sup>10</sup> and the 1kGP data,<sup>9</sup> and 1,676 cases and 5,237 controls with de novo genotyping (Tables S1, S2, and S4). All 11 SNPs were either directly genotyped or had a high imputation information score (average information score = 0.92). Genotyping of these 11 SNPs by TaqMan (Applied Biosystems) in 470 subjects from the NCI GWAS yielded  $>88.9\%$  concordance with the imputed dosages (median concordance = 99.6%), indicating that imputation accuracy was high. Association testing was conducted for each study using either GLU (de novo genotyping) or SNPTTEST (UCSF1/NHS), adjusting for relevant factors.

Results from the stage 1 and 2 studies were then meta-analyzed using a fixed effects model. In the combined meta-analysis, we found five non-HLA loci that achieved genome-wide significance ( $p < 5 \times 10^{-8}$ ) at 11q23.3 (rs4938573,  $p = 5.79 \times 10^{-20}$ ), 11q24.3 (rs4937362,  $p = 6.76 \times 10^{-11}$ ), 3q28 (rs6444305,  $p = 1.10 \times 10^{-10}$ ),



**Figure 2. Regional Plots of the FL-Associated Locus rs4937362 in 11q24.3**

Figure shows the association results from the NCI NHL GWAS and stages 1 and 2 combined (red diamond), recombination hotspots, and LD plots.


8q24.21 maps near the oncogene, plasmacytoma variant translocation 1 gene (*PVT1* [MIM 165140]) (Figure 5). Characteristics of these loci are presented in Table S5. The suggestive SNP rs3751913 is in chromosome 17 opening reading frame 62 (*C17orf62*); rs2681416 is in CD86 molecule (*CD86*) (MIM 601020); and rs11082438 is in solute carrier 14A2 (*SLC14A2* [MIM 601611]) (Table 1, Figure S6). Using the Cochran's Q test and by estimating the  $I^2$  heterogeneity index, no substantial heterogeneity was observed among the studies for any SNP ( $p_{\text{heterogeneity}} \geq 0.05$ ) except for the suggestive locus, rs2681416 at 3q13.33 (Table 1). Although the p value for heterogeneity for rs13254990 was borderline significant, all of the effect estimates for the individual studies were above 1.0.

18q21.33 (rs17749561,  $p = 8.28 \times 10^{-10}$ ), and 8q24.21 (rs13254990,  $p = 1.06 \times 10^{-8}$ ); and three suggestive loci ( $p < 5 \times 10^{-7}$ ) at 17q25.3 (rs3751913,  $p = 2.24 \times 10^{-7}$ ), 3q13.33 (rs2681416,  $p = 2.33 \times 10^{-7}$ ), and 18q12.3 (rs11082438,  $p = 4.01 \times 10^{-7}$ ) (Table 1). Two of the five loci that reached genome-wide significance in the stage 1 and 2 meta-analysis (11q23.3 and 11q24.3) were genome-wide significant in the stage 1 meta-analysis and were robustly replicated in stage 2 ( $p = 3.17 \times 10^{-10}$  and  $p = 0.0002$ , respectively). The remaining three loci achieved genome-wide significance after inclusion of the stage 2 data and therefore would benefit from further validation in other independent samples.

rs4938573 at 11q23.3 maps 12.6 kb upstream of the chemokine (c-x-c motif) receptor 5 gene (*CXCR5* [MIM 601613]) (Figure 1). The 11q24.3 locus marked by rs4937362 ( $p = 6.76 \times 10^{-11}$ ) is approximately 35 kb upstream of v-ets avian erythroblastosis virus E26 oncogene homolog 1 (*ETS1* [MIM 164720]) (Figure 2). The 3q28 locus marked by rs6444305 maps to a region that overlaps the LIM domain containing preferred translocation partner in lipoma (*LPP* [MIM 600700]) and is 836.4 kb upstream of *BCL6* (MIM 109565) (Figure 3). rs17749561 in 18q21.33 is located 7.4 kb downstream of the antiapoptotic oncogene, B cell CLL/lymphoma 2 (*BCL2* [MIM 151430]) (Figure 4); and rs13254990 at

To explore potential functional roles for associated SNPs and their surrogates ( $r^2 > .80$ ) and to assess the B cell-specific chromatin dynamics of regions overlapping with the associated SNPs, we conducted HaploReg<sup>11</sup> and ChromoS analyses.<sup>12,13</sup> Here we found that three loci, 11q23.3, 3q13.33, and 8q24.21, were annotated as overlapping enhancers in the lymphoblastoid cell line GM12878,<sup>14</sup> suggesting that our GWAS signals map to variants that overlap within regions of active chromatin state in B cells (Table S6; Figure S7). However, an expression quantitative trait loci (eQTL) analysis using publicly available RNA sequencing data on lymphoblastoid cell lines (available from the Gene Expression Omnibus [GEO] repository under accession number GSE16921) yielded no notable ( $FDR < 0.05$ ) associations of the selected SNPs with gene expression levels. Additional analysis using microarray data (GEO accession number GSE8052) did not reveal any significant eQTL associations for the genome-wide significant loci, although the suggestive SNP, rs3751913, was associated with *C17orf62* expression (data not shown). Thus, further work is needed to identify and characterize the biological basis of these FL susceptibility alleles.

Consistent with previous smaller reports, the strongest effects on FL risk were observed in the HLA region at 6p21.32-33, where 8,104 SNPs achieved genome-wide



**Figure 3. Regional Plots of the Associated Locus rs6444305 in 3q28**


Figure shows the association results from the NCI FL GWAS and stages 1 and 2 combined (red diamond), recombination hotspots, and LD plots.

“multiallelic” with three to six different residues present at each position, were successfully imputed (information score > 0.3 for SNPs or  $r^2 > 0.3$  for alleles and AAs) and available for downstream analysis. Association testing was conducted using PLINK,<sup>18</sup> where multiallelic markers were analyzed as binary markers (e.g., allele present or absent). A meta-analysis was conducted where we tested SNPs, HLA alleles, and AAs across the HLA region for association to FL. Among the imputed AAs and HLA alleles tested, the top associated signal mapped to a DR $\beta$ 1 AA at position 28 that carries three possible amino acids: Glu, Asp, and His. Asp was associated with low (OR = 0.53;  $p = 6.1 \times 10^{-72}$ ) and Glu with high (OR = 1.86;  $p = 7.99 \times 10^{-69}$ ) FL risk (Table S7). Global omnibus tests of position 28 ( $2.49 \times 10^{-67} \leq p \leq 3.84 \times 10^{-67}$ )

significance ( $p < 5 \times 10^{-8}$ ) in the stage 1 meta-analysis (Figure S8). One top SNP, rs12195582, was carried forward for replication in stage 2 and reached a combined  $p = 5.36 \times 10^{-100}$  in stages 1+2 (Table 1). To further refine the association of HLA variants with FL risk and determine whether specific coding variants within HLA genes contributed to the diverse association signals, we imputed classical HLA alleles and amino acids (AAs) at seven loci (*HLA-A* [MIM 142800], *HLA-B* [MIM 142830], *HLA-C* [MIM 142840], *HLA-DQA1* [MIM 146880], *HLA-DQB1* [MIM 604305], *HLA-DRB1* [MIM 142857], and *HLA-DPB1* [MIM 142858]) on the four GWAS data sets from stages 1+2 (NCI, USCF2, SCALE, UCSF1/NHS) using SNP2HLA<sup>15</sup> and a reference panel from the Type 1 Diabetes Genetics Consortium (T1DGC) consisting of genotype data from 5,225 individuals of European descent that were typed for classical HLA alleles. The imputation accuracy of HLA types was high (>95.23%) when compared to HLA sequencing data on a subset of NCI and UCSF2 samples scanned as part of this study.<sup>16,17</sup> Due to the limited number of SNPs (7,253) in the T1DGC reference set, imputation of HLA SNPs was conducted with IMPUTE2 and the 1kGP reference set. A total of 68,488 SNPs, 201 classical HLA alleles (two- and four-digit resolution), and 1,038 AA markers including 103 AA positions that were

and other nearby DR $\beta$ 1 AA positions at 11, 13, and 30 yielded statistically similar associations with FL risk (Table S9). These results support the previously reported association between FL and DR $\beta$ 1 position 13 in a small study of Europeans.<sup>19</sup> However, due to the high LD between positions 11, 13, 28, and 30, we were unable to determine the significance of one position at the exclusion of the other through reciprocal conditional analyses. The most significant imputed two- or four-digit HLA allele in our analysis was *DRB1\*01* (OR = 1.85;  $p = 2.57 \times 10^{-42}$ ) (Table S7), encoded by Glu28, Cys30, Phe13, and Leu11 (Table S9). An association with FL risk was found for *HLA-DRB1\*07:01* that is also encoded by residues at 11, 13, 28, and 30 ( $p = 1.59 \times 10^{-20}$ ) (Table S9). Positions 11, 13, 28, and 30 reside in the middle of the HLA-DR heterodimer molecule in the peptide binding cleft (Figure S9) that specifically impact binding pockets 4, 6, and 7. These are key peptide binding anchors in DR $\beta$ 1<sup>20</sup> that influence binding preferences of alleles,<sup>21</sup> suggesting an important role for DR $\beta$ 1 peptide presentation in follicular lymphomagenesis.

To identify independent HLA variants controlling for DR $\beta$ 1 28 (used as a surrogate for the 11, 13, 28, and 30 group), we included all genotyped and imputed HLA SNPs, AAs, and alleles in a forward stepwise analysis. The most significant variant after controlling for DR $\beta$ 1 28 was



**Figure 4. Regional Plots of the Associated Locus rs17749561 in 18q21.33**

Figure shows the association results from the NCI FL GWAS and stages 1 and 2 combined (red diamond), recombination hotspots, and LD plots.

613503], *BTNL2* [MIM 606000], *C6orf25*); and with rs3130439, a proxy for rs3130437, in HLA class I (*PSORS1C2*, *PSORS1C3*, *DPCR1* [MIM 613928]) (Table S12). Of note, ten of the rs17203612-linked SNPs that showed correlation with higher *HLA-DQB1* expression also showed correlation with lower *HLA-DQB1* methylation levels (Table S12) that further supports the potential role of HLA class II FL-associated SNPs in *HLA-DQB1* regulation.<sup>24,25</sup> Additional eQTL analyses using microarray data also suggested potential eQTL associations with *HLA-C*, *TCF19* (MIM 600912), and *HLA-B* expression (Table S14). However, we did not observe significant enrichment of particular regulatory markers within these associated regions, although overlap with some regulatory signals was observed (Table S15).

rs17203612 ( $p = 4.59 \times 10^{-16}$ ), an intergenic SNP 39.2 kb and 99.7 kb downstream of *HLA-DRA* (MIM 142860) and *HLA-DRB1*, respectively (Figure 6; Table S10). A conditional analysis on DR $\beta$ 1 28 and rs17203612 revealed that the next most statistically significant variant was rs3130437 ( $p = 8.23 \times 10^{-9}$ ) located 15.6 kb downstream of *HLA-C* in HLA class I (Figure 6; Table S10). After controlling for DR $\beta$ 1 28, rs17203612, and rs3130437, no additional signals with  $p < 5 \times 10^{-8}$  were observed (Figure 6). Of note, we did see a residual signal ( $p = 8.18 \times 10^{-6}$ ) at the functionally relevant DP $\beta$ 1 Glu84 position,<sup>22</sup> a reported risk locus for Hodgkin lymphoma.<sup>23</sup> A conditional analysis of DR $\beta$ 1 28, rs17203612, and rs3130437 eliminated the majority of residual effects for the previously reported HLA SNPs and alleles associated with FL (Table S11).

We conducted a series of preliminary bioinformatics analyses to explore the potential functional relevance of rs17203612 and rs3130437 using publicly available RNA sequencing expression and methylation data and found significant (FDR < 0.05) gene expression and methylation differences associated with rs17203612- and rs3130437-linked SNPs (Tables S12 and S13). Specifically, we found significant gene expression changes associated with rs12194148, a proxy for rs17203612, in class II (*HLA-DRB5* [MIM 604776], *HLA-DRB6*, *HLA-DRB1*, *HLA-DQB1*, *HLA-DQB2* [MIM 615161], *HLA-DQA1*, *HLA-DQA2* [MIM

In summary, our study identified five non-HLA susceptibility alleles that were robustly associated with FL risk. Moreover, our work highlights the important role of HLA structural variants and regulatory SNPs in the etiology of FL, advances the catalog of HLA and non-HLA genetic variants associated with FL risk, and provides further evidence for a role of DR $\beta$ 1 peptide presentation in FL. Functional studies will be required to elucidate the biological basis of these loci and to determine their role in follicular lymphomagenesis.

### Supplemental Data

Supplemental Data include 9 figures, 15 tables, and Supplemental Acknowledgments and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2014.09.004>.


### Acknowledgments

The overall FL GWAS project was supported by the intramural program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH. A full list of Supplemental Acknowledgments is provided online.

Received: July 17, 2014

Accepted: September 10, 2014

Published: October 2, 2014



**Figure 5. Regional Plots of the Associated Locus rs13254990 in 8q24.21**

Figure shows the association results from the NCI FL GWAS and stages 1 and 2 combined (red diamond), recombination hot-spots, and LD plots.

## Web Resources


The URLs for data presented herein are as follows:

1000 Genomes, <http://browser.1000genomes.org>  
 ChroMoS, <http://epicenter.immunbio.mpg.de/services/chromos>  
 Gene Expression Omnibus (GEO), <http://www.ncbi.nlm.nih.gov/geo/>  
 glu-genetics, <https://code.google.com/p/glu-genetics/>  
 HaploReg, <http://www.broadinstitute.org/mammals/haploreg/haploreg.php>  
 IMPUTE2, [http://mathgen.stats.ox.ac.uk/impute/impute\\_v2.html](http://mathgen.stats.ox.ac.uk/impute/impute_v2.html)  
 Online Mendelian Inheritance in Man (OMIM), <http://www.omim.org/>  
 PLINK, <http://pngu.mgh.harvard.edu/~purcell/plink/>  
 SNP2HLA, <https://www.broadinstitute.org/mpg/snp2hla/>  
 snptest, [https://mathgen.stats.ox.ac.uk/genetics\\_software/snptest/old/snptest.html](https://mathgen.stats.ox.ac.uk/genetics_software/snptest/old/snptest.html)

## References

- Link, B.K., Maurer, M.J., Nowakowski, G.S., Ansell, S.M., Macon, W.R., Syrbu, S.I., Slager, S.L., Thompson, C.A., Inwards, D.J., Johnston, P.B., et al. (2013). Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. *J. Clin. Oncol.* *31*, 3272–3278.
- Tan, D., Horning, S.J., Hoppe, R.T., Levy, R., Rosenberg, S.A., Sigal, B.M., Warnke, R.A., Natkunam, Y., Han, S.S., Yuen, A., et al. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. *Blood* *122*, 981–987.
- Smedby, K.E., Foo, J.N., Skibola, C.F., Darabi, H., Conde, L., Hjalgrim, H., Kumar, V., Chang, E.T., Rothman, N., Cerhan, J.R., et al. (2011). GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. *PLoS Genet.* *7*, e1001378.
- Conde, L., Halperin, E., Akers, N.K., Brown, K.M., Smedby, K.E., Rothman, N., Nieters, A., Slager, S.L., Brooks-Wilson, A., Agana, L., et al. (2010). Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. *Nat. Genet.* *42*, 661–664.
- Skibola, C.F., Bracci, P.M., Halperin, E., Conde, L., Craig, D.W., Agana, L., Iyadurai, K., Becker, N., Brooks-Wilson, A., Curry, J.D., et al. (2009). Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. *Nat. Genet.* *41*, 873–875.
- Vijai, J., Kirchhoff, T., Schrader, K.A., Brown, J., Dutra-Clarke, A.V., Manschreck, C., Hansen, N., Rau-Murthy, R., Sarrel, K., Przybylo, J., et al. (2013). Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. *PLoS Genet.* *9*, e1003220.
- Skibola, C.F., Conde, L., Foo, J.N., Riby, J., Humphreys, K., Sillé, F.C., Darabi, H., Sanchez, S., Hjalgrim, H., Liu, J., et al.





**Figure 6. Sequential Conditioned Association Analysis in the HLA Region at 6p22.1-21.32: 29,400–33,400 kb**

Each gray diamond represents the p value from the meta-analysis of the four GWASs. Among all the AAs and HLA alleles tested, the top associated signal mapped to the AA DRβ1 at position 28 (top). After conditioning on DRβ1 28, rs17203612 in the HLA class II region was the marker with the highest association (second from top). Further analysis conditioning on both signals revealed rs3130437 in HLA class I as the most significant associated marker (second from bottom). No additional genome-wide significant signals were observed after controlling for the effects of DRβ1 28, rs17203612, and rs3130437 (bottom). Plots derived using genome assembly hg19.

(2012). A meta-analysis of genome-wide association studies of follicular lymphoma. *BMC Genomics* 13, 516.

8. Wang, Z., Jacobs, K.B., Yeager, M., Hutchinson, A., Sampson, J., Chatterjee, N., Albanes, D., Berndt, S.I., Chung, C.C., Diver, W.R., et al. (2012). Improved imputation of common and uncommon SNPs with a new reference set. *Nat. Genet.* 44, 6–7.
9. Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin, R.M., Gibbs, R.A., Hurles, M.E., and McVean, G.A.; 1000 Genomes Project Consortium (2010). A map of human genome variation from population-scale sequencing. *Nature* 467, 1061–1073.
10. Howie, B.N., Donnelly, P., and Marchini, J. (2009). A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* 5, e1000529.
11. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* 40 (Database issue), D930–D934.
12. Barenboim, M., and Manke, T. (2013). ChroMoS: an integrated web tool for SNP classification, prioritization and functional interpretation. *Bioinformatics* 29, 2197–2198.
13. Ernst, J., Kheradpour, P., Mikkelson, T.S., Shores, N., Ward, L.D., Epstein, C.B., Zhang, X., Wang, L., Issner, R., Coyne, M., et al. (2011). Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* 473, 43–49.
14. Consortium, E.P., Bernstein, B.E., Birney, E., Dunham, I., Green, E.D., Gunter, C., and Snyder, M.; ENCODE Project Consortium (2012). An integrated encyclopedia of DNA elements in the human genome. *Nature* 489, 57–74.
15. Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.M., Concannon, P.J., Rich, S.S., Raychaudhuri, S., and de Bakker, P.I. (2013). Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS ONE* 8, e64683.
16. Wang, S.S., Abdou, A.M., Morton, L.M., Thomas, R., Cerhan, J.R., Gao, X., Cozen, W., Rothman, N., Davis, S., Severson, R.K., et al. (2010). Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. *Blood* 115, 4820–4823.
17. Skibola, C.F., Akers, N.K., Conde, L., Ladner, M., Hawbecker, S.K., Cohen, F., Ribas, F., Erlich, H.A., Goodridge, D., Trachtenberg, E.A., et al. (2012). Multi-locus HLA class I and II allele and haplotype associations with follicular lymphoma. *Tissue Antigens* 79, 279–286.
18. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* 81, 559–575.
19. Foo, J.N., Smedby, K.E., Akers, N.K., Berglund, M., Irwan, I.D., Jia, X., Li, Y., Conde, L., Darabi, H., Bracci, P.M., et al. (2013). Coding variants at hexa-allelic amino acid 13 of HLA-DRB1

- explain independent SNP associations with follicular lymphoma risk. *Am. J. Hum. Genet.* *93*, 167–172.
20. Stern, L.J., Brown, J.H., Jardetzky, T.S., Gorga, J.C., Urban, R.G., Strominger, J.L., and Wiley, D.C. (1994). Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. *Nature* *368*, 215–221.
21. Rapin, N., Hoof, I., Lund, O., and Nielsen, M. (2010). The MHC motif viewer: a visualization tool for MHC binding motifs. *Curr. Protoc. Immunol. Unit* *18*, 17.
22. Díaz, G., Amicosante, M., Jaraquemada, D., Butler, R.H., Guillén, M.V., Sánchez, M., Nombela, C., and Arroyo, J. (2003). Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. *Int. Immunol.* *15*, 565–576.
23. Taylor, G.M., Gokhale, D.A., Crowther, D., Woll, P.J., Harris, M., Ryder, D., Ayres, M., and Radford, J.A. (1999). Further investigation of the role of HLA-DPB1 in adult Hodgkin's disease (HD) suggests an influence on susceptibility to different HD subtypes. *Br. J. Cancer* *80*, 1405–1411.
24. Conde, L., Bracci, P.M., Richardson, R., Montgomery, S.B., and Skibola, C.F. (2013). Integrating GWAS and expression data for functional characterization of disease-associated SNPs: an application to follicular lymphoma. *Am. J. Hum. Genet.* *92*, 126–130.
25. Sillé, F.C., Conde, L., Zhang, J., Akers, N.K., Sanchez, S., Maltbaek, J., Riby, J.E., Smith, M.T., and Skibola, C.F. (2014). Follicular lymphoma-protective HLA class II variants correlate with increased HLA-DQB1 protein expression. *Genes Immun.* *15*, 133–136.